[go: up one dir, main page]

WO2026022712A1 - Modulateur de ligase céréblon et polythérapie d'activation de cellules nk bcma - Google Patents

Modulateur de ligase céréblon et polythérapie d'activation de cellules nk bcma

Info

Publication number
WO2026022712A1
WO2026022712A1 PCT/IB2025/057431 IB2025057431W WO2026022712A1 WO 2026022712 A1 WO2026022712 A1 WO 2026022712A1 IB 2025057431 W IB2025057431 W IB 2025057431W WO 2026022712 A1 WO2026022712 A1 WO 2026022712A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
seq
acid sequence
sequence
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2025/057431
Other languages
English (en)
Inventor
Marielle Chiron
Helgi Van De Velde
Angela VIRONE-ODDOS
Alexandre DESJONQUERES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of WO2026022712A1 publication Critical patent/WO2026022712A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente divulgation concerne une méthode de traitement du cancer (par exemple, le myélome multiple) avec la combinaison de i) une protéine de liaison multifonctionnelle comprenant un premier et un second domaine de liaison à l'antigène (ABD), le premier ABD se liant de manière spécifique au BCMA humain et le second ABD se liant de manière spécifique au NKp46 humain ; et ii) un agent de modulation de céréblon.
PCT/IB2025/057431 2024-07-23 2025-07-23 Modulateur de ligase céréblon et polythérapie d'activation de cellules nk bcma Pending WO2026022712A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP24306234.6 2024-07-23
EP24306234 2024-07-23

Publications (1)

Publication Number Publication Date
WO2026022712A1 true WO2026022712A1 (fr) 2026-01-29

Family

ID=92503879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2025/057431 Pending WO2026022712A1 (fr) 2024-07-23 2025-07-23 Modulateur de ligase céréblon et polythérapie d'activation de cellules nk bcma

Country Status (1)

Country Link
WO (1) WO2026022712A1 (fr)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009817A1 (fr) 1992-11-04 1994-05-11 City Of Hope Nouvelle structure d'anticorps
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
WO2002002781A1 (fr) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Proteines de fusion heterodimeres
WO2009080253A1 (fr) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Anticorps bivalents bispécifiques
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20100226923A1 (en) 2007-10-15 2010-09-09 Sanofi-Aventis Antibodies that bind il-4 and/or il-13 and their uses
US20110196150A1 (en) 2010-02-11 2011-08-11 Hon-Wah Man Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same
WO2012135345A1 (fr) 2011-03-28 2012-10-04 Sanofi Protéines de liaison à des anticorps-like à double région variable ayant une orientation croisée de région de liaison
WO2014153063A1 (fr) 2013-03-14 2014-09-25 Amgen Inc. Polypeptides contenant fc aglycosylés
EP2940135A1 (fr) 2012-12-27 2015-11-04 Chugai Seiyaku Kabushiki Kaisha Polypeptide hétérodimérisé
WO2017180913A2 (fr) 2016-04-13 2017-10-19 Sanofi Protéines de liaison trispécifiques et/ou trivalentes
WO2019147973A1 (fr) 2018-01-26 2019-08-01 Genzyme Corporation Variants fc présentant une liaison améliorée à fcrn et demi-vie prolongée
WO2022053652A1 (fr) * 2020-09-11 2022-03-17 Engmab Sàrl Polythérapie contre le cancer
US20240034816A1 (en) * 2022-05-27 2024-02-01 Sanofi NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND BCMA VARIANTS WITH FC-ENGINEERING

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009817A1 (fr) 1992-11-04 1994-05-11 City Of Hope Nouvelle structure d'anticorps
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
WO2002002781A1 (fr) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Proteines de fusion heterodimeres
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20100226923A1 (en) 2007-10-15 2010-09-09 Sanofi-Aventis Antibodies that bind il-4 and/or il-13 and their uses
WO2009080253A1 (fr) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Anticorps bivalents bispécifiques
US20110196150A1 (en) 2010-02-11 2011-08-11 Hon-Wah Man Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same
WO2012135345A1 (fr) 2011-03-28 2012-10-04 Sanofi Protéines de liaison à des anticorps-like à double région variable ayant une orientation croisée de région de liaison
US20120251541A1 (en) 2011-03-28 2012-10-04 Sanofi Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
EP2940135A1 (fr) 2012-12-27 2015-11-04 Chugai Seiyaku Kabushiki Kaisha Polypeptide hétérodimérisé
WO2014153063A1 (fr) 2013-03-14 2014-09-25 Amgen Inc. Polypeptides contenant fc aglycosylés
WO2017180913A2 (fr) 2016-04-13 2017-10-19 Sanofi Protéines de liaison trispécifiques et/ou trivalentes
WO2019147973A1 (fr) 2018-01-26 2019-08-01 Genzyme Corporation Variants fc présentant une liaison améliorée à fcrn et demi-vie prolongée
WO2022053652A1 (fr) * 2020-09-11 2022-03-17 Engmab Sàrl Polythérapie contre le cancer
US20240034816A1 (en) * 2022-05-27 2024-02-01 Sanofi NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND BCMA VARIANTS WITH FC-ENGINEERING

Non-Patent Citations (51)

* Cited by examiner, † Cited by third party
Title
"Antibody-antigen interactions: Contact analysis and binding site topography", J. MOL. BIOL., vol. 262, pages 732 - 745
"Natural Killer Cells Protocols", 2000, HUMAN PRESS, pages: 219 - 238
"NCBI", Database accession no. NM 004829
AL-LAZIKANI ET AL., J. MOL. BIOL., vol. 273, 1997, pages 927 - 948
AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948
ANGERS ET AL., NATURE, vol. 443, no. 7111, 2006, pages 590 - 3
AUSUBE ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH
BOYD ET AL., MOL. IMMUNOL, vol. 32, 1996, pages 1311 - 1318
CERWENKALANIER, SCIENCE, vol. 359, 2018, pages 6383
CHO SHIH-FENG ET AL: "The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models", vol. 4, no. 17, 8 September 2020 (2020-09-08), pages 4195 - 4207, XP093237674, ISSN: 2473-9529, Retrieved from the Internet <URL:https://pmc.ncbi.nlm.nih.gov/articles/PMC7479960/pdf/advancesADV2020002524.pdf> DOI: 10.1182/bloodadvances.2020002524 *
CHOTHIA ET AL., J. MOL. BIOL., vol. 227, 1992, pages 799 - 817
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
DAVIS ET AL., CHEM. REV, vol. 102, 2002, pages 579
DEMARIA ET AL., EUR. J. IMMUNOLOGY, vol. 51, no. 8, 2021, pages 1934
FEIGE ET AL., J. MOL. BIOL, vol. 344, 2004, pages 107 - 118
GAUTHIER ET AL., CELL, vol. 177, 2019, pages 1701 - 13
GODARA ET AL., BLOOD, vol. 134, 2019, pages 4409
GONG ET AL., J. BIOL. CHEM., vol. 284, 2009, pages 14203 - 210
HANG ET AL., ACC. CHEM. RES, vol. 34, 2001, pages 727
HARMSENDE HAARD H J, APPL. MICROBIOL. BIOTECHNOL, vol. 77, no. 1, November 2007 (2007-11-01), pages 13 - 22
HONEGGER APLUCKTHUN A: "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool", J MOL BIOL, vol. 309, no. 3, 8 June 2001 (2001-06-08), pages 657 - 70, XP004626893, DOI: 10.1006/jmbi.2001.4662
HONNEGGERPLUCKTHUN, J. MOL. BIOL., vol. 309, no. 3, 2001, pages 657 - 670
JACOBSEN ET AL., J. BIOL. CHEM., vol. 202, 2017, pages 1865 - 75
LAABI Y ET AL., NUCLEIC ACIDS RES., vol. 22, 1994, pages 1147 - 1154
LEABMAN ET AL., MABS, vol. 5, 2013, pages 896 - 903
LEFRANC ET AL., DEVELOPMENTAL & COMPARATIVE IMMUNOLOGY, vol. 27, 2003, pages 55 - 77
LEFRANC ET AL., NUCLEIC ACIDS RES., vol. 27, 1999, pages 209 - 212
LEFRANC M P ET AL.: "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains", DEV COMP IMMUNOL, vol. 27, no. 1, January 2003 (2003-01-01), pages 55 - 77, XP055585227, DOI: 10.1016/S0145-305X(02)00039-3
LEFRANC, THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
LI ET AL., J INT MED RES., vol. 47, no. 4, 2019, pages 1778 - 1786
LIU ET AL., J. BIOL. CHEM, vol. 289, no. 6, 2014, pages 3571
LIU, ANTIBODIES, vol. 9, no. 4, 2020, pages 64
LO NIGRO, ANN TRANSL MED, vol. 7, 2019, pages 105
MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745
MACKNESS ET AL., MABS, vol. 11, 2019, pages 1276 - 88
PICKEN, ACTA HAEMATOL, vol. 143, 2020, pages 322 - 334
RAJU ET AL., BIOCHEMISTRY, vol. 40, 2001, pages 8868 - 8876
ROUX ET AL., J. IMMUNOL, vol. 161, 1998, pages 4083
SAUNDERS, FRONT. IMMUNOL, 2009
SCHAEFER ET AL., PNAS, vol. 108, 2011, pages 11187 - 1191
SEARS ET AL., SCIENCE, vol. 291, 2001, pages 2344
SMIRNOVA A S ET AL., MOL IMMUNOL., vol. 45, no. 4, 2008, pages 1179 - 1183
TANG ALEXANDRE ET AL: "The Combination of the Novel Trifunctional BCMA NK Cell Engager SAR445514 with IMiDs and Celmods Enhances Cytotoxicity Against Multiple Myeloma Cells As Compared to Single Agents", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 144, 5 November 2024 (2024-11-05), pages 6846, XP087661845, ISSN: 0006-4971, [retrieved on 20241206], DOI: 10.1182/BLOOD-2024-203571 *
TANG ET AL., AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 83, 2023, pages 2960
TANG ET AL: "Abstract 2960: The novel trifunctional anti-BCMA NK cell engager SAR'514 has potent in-vitro, in-vivo and ex-vivo anti-myeloma effect through dual NK cell engagement | Cancer Research | American Association for Cancer Research", vol. 83, no. 7_Supplement, 4 April 2023 (2023-04-04), US, pages 2960 - 2960, XP093236499, ISSN: 1538-7445, Retrieved from the Internet <URL:https://aacrjournals.org/cancerres/article/83/7_Supplement/2960/723812/Abstract-2960-The-novel-trifunctional-anti-BCMA-NK> DOI: 10.1158/1538-7445.AM2023-2960 *
TOYAMAWEISSMAN, ANNU REV BIOCHEM, vol. 80, no. 2259648-80-9, 2011, pages 557 - 585
TRAMONTANO A ET AL., J. MOL. BIOL., vol. 215, no. 1, 1990, pages 175 - 82
WACKER ET AL., SCIENCE, vol. 298, 2002, pages 1790
WEN ET AL., ANAL. BIOCHEM, vol. 593, 2020, pages 113581
WOZNIAK-KNOPP ET AL., PLOS ONE, vol. 7, 2012, pages e30083
ZHANG ET AL., SCIENCE, vol. 303, 2004, pages 371

Similar Documents

Publication Publication Date Title
US20240124599A1 (en) Anti-bcma heavy chain-only antibodies
US20230060847A1 (en) Anti-bcma heavy chain-only antibodies
US11434299B2 (en) Anti-BCMA heavy chain-only antibodies
KR101670088B1 (ko) 아밀로이드 베타에 대해 인간화된 항체
US12428482B2 (en) Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
US12195555B2 (en) Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with Fc-engineering
TW202231292A (zh) 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
US20240309100A1 (en) Anti-Trkb Monoclonal Antibodies And Methods Of Use
JP7702428B2 (ja) 抗ｇｌｐ１ｒアンタゴニスト抗体およびその使用方法
CN111683966A (zh) 与cd22结合的重链抗体
WO2009040336A1 (fr) Protéines de liaison aux antigènes
JP2024507540A (ja) 抗ｐｓｍａ抗体及びｃａｒ－ｔ構造
JP2024513951A (ja) 抗ｃｄ２０抗体及びｃａｒ－ｔ構造
TW202233684A (zh) 結合於葉酸受體α之重鏈抗體
US20230107034A1 (en) Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer&#39;s disease
IL295471A (en) Anti-bcma therapy in autoimmune disorders
WO2026022712A1 (fr) Modulateur de ligase céréblon et polythérapie d&#39;activation de cellules nk bcma
TW202506728A (zh) 活化素a受體樣1型(alk1)之雙特異性促效性抗體
CN121057752A (zh) 铰链经修饰的双特异性抗体
TW202432596A (zh) 針對磷脂醯肌醇蛋白聚醣3的雙特異性抗體及其應用
US20240301061A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
US20240301062A1 (en) Anti-cd3 multispecific antibodies and methods of use
RU2807484C2 (ru) Антитело к pd-1, его антигенсвязывающий фрагмент и его фармацевтическое применение
HK40095391A (en) Anti-bcma heavy chain-only antibodies
CN119264263A (zh) 靶向pd-1和lag3的双特异性抗体及其用途